Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Assets Average (2022 - 2025)

Corvus Pharmaceuticals has reported Assets Average over the past 4 years, most recently at $85.0 million for Q3 2025.

  • Quarterly results put Assets Average at $85.0 million for Q3 2025, up 37.74% from a year ago — trailing twelve months through Sep 2025 was $85.0 million (up 37.74% YoY), and the annual figure for FY2024 was $57.2 million, up 0.59%.
  • Assets Average for Q3 2025 was $85.0 million at Corvus Pharmaceuticals, up from $74.4 million in the prior quarter.
  • Over the last five years, Assets Average for CRVS hit a ceiling of $96.9 million in Q2 2022 and a floor of $42.8 million in Q1 2024.
  • Median Assets Average over the past 4 years was $63.5 million (2023), compared with a mean of $66.2 million.
  • Biggest five-year swings in Assets Average: tumbled 40.03% in 2023 and later surged 49.87% in 2025.
  • Corvus Pharmaceuticals' Assets Average stood at $74.3 million in 2022, then tumbled by 34.39% to $48.7 million in 2023, then soared by 31.0% to $63.9 million in 2024, then skyrocketed by 33.05% to $85.0 million in 2025.
  • The last three reported values for Assets Average were $85.0 million (Q3 2025), $74.4 million (Q2 2025), and $64.2 million (Q1 2025) per Business Quant data.